Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29869865 | 0.81 | SLCO1B1 (0.35) | KDM4CSLCO1B1NPC1RAB9ALPAR1 | |
| SCHEMBL21107344 | 0.81 | SLCO1B1 (0.35) | KDM4CSLCO1B1NPC1RAB9ALPAR1 | |
| SCHEMBL29868781 | 0.81 | KDM4C (0.34) | KDM4CSLCO1B1NPC1RAB9ALPAR1 | |
| SCHEMBL21107114 | 0.81 | KDM4C (0.34) | KDM4CSLCO1B1NPC1RAB9ALPAR1 | |
| SCHEMBL27157474 | 0.78 | ABCC3 (0.34) | SLCO1B1LPAR1 | |
| SCHEMBL21807773 | 0.77 | LPAR1 (0.37) | KDM4CSLCO1B1NPC1RAB9ALPAR1 | |
| SCHEMBL25237116 | 0.76 | SLCO1B1 (0.55) | SLCO1B1LPAR1 | |
| SCHEMBL31614992 | 0.76 | L3MBTL1 (0.34) | KDM4CNPC1RAB9A | |
| SCHEMBL29634339 | 0.76 | SLCO1B1 (0.37) | KDM4CSLCO1B1NPC1RAB9ALPAR1 | |
| SCHEMBL22467484 | 0.76 | SLCO1B1 (0.37) | KDM4CSLCO1B1NPC1RAB9ALPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3728209-B1 | CYCLOHEXYL ACID ISOXAZOLE AZINES AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12209072-B2 | Cyclopentyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-01-28 | — | — | US | disclosed |
| EP-3728242-B1 | CYCLOHEXYL ACID ISOXAZOLE AZOLES AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-03-01 | — | — | EP | disclosed |
| EP-3728242-B1 | CYCLOHEXYL ACID ISOXAZOLE AZOLES AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-03-01 | — | — | EP | disclosed |
| EP-3728240-B1 | ISOXAZOLE O-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2022-06-29 | — | — | EP | disclosed |
| EP-3728240-B1 | ISOXAZOLE O-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2022-06-29 | — | — | EP | disclosed |
| US-11319309-B2 | Cyclohexyl acid isoxazole azines as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-05-03 | — | — | US | disclosed |
| US-11319309-B2 | Cyclohexyl acid isoxazole azines as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-05-03 | — | — | US | disclosed |
| US-11261180-B2 | Cyclohexyl acid isoxazole azoles as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-03-01 | — | — | US | disclosed |
| US-11180488-B2 | Isoxazole o-linked carbamoyl cyclohexyl acids as LPA antagonists | BRISTOL MYERS SQUIBB CO (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3728209-A1 | CYCLOHEXYL ACID ISOXAZOLE AZINES AS LPA ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2020-10-28 | — | — | EP | disclosed |
| US-20200317662-A1 | CYCLOHEXYL ACID ISOXAZOLE AZOLES AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-10-08 | — | — | US | disclosed |
| US-20200317662-A1 | CYCLOHEXYL ACID ISOXAZOLE AZOLES AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-10-08 | — | — | US | disclosed |
| US-20200317656-A1 | CYCLOHEXYL ACID ISOXAZOLE AZINES AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-10-08 | — | — | US | disclosed |
| US-20200317656-A1 | CYCLOHEXYL ACID ISOXAZOLE AZINES AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-10-08 | — | — | US | disclosed |
| US-20200317655-A1 | ISOXAZOLE O-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-10-08 | — | — | US | disclosed |
| US-20200317655-A1 | ISOXAZOLE O-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-10-08 | — | — | US | disclosed |
| CN-111479807-A | Cyclohexyl acid isoxazoles azines as L PA antagonists | 百时美施贵宝公司 | 2020-07-31 | — | — | CN | disclosed |
| WO-2020060915-A1 | CYCLOPENTYL ACIDS AS LPA ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-03-26 | — | — | WO | disclosed |
| WO-2019126084-A1 | ISOXAZOLE O-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11261180-B2 | Cyclohexyl acid isoxazole azoles as LPA antagonists | LPAR1, LPAR2, LPAR3 | KDM4C 3852/4885SLCO1B1 724/4885NPC1 635/4885 |
| US-11319309-B2 | Cyclohexyl acid isoxazole azines as LPA antagonists | LPAR1, LPAR2, LPAR5 | KDM4C 4092/4885SLCO1B1 1008/4885NPC1 452/4885 |
| US-12209072-B2 | Cyclopentyl acids as LPA antagonists | LPAR1, LPAR5, LPAR2 | KDM4C 4235/4885SLCO1B1 724/4885NPC1 302/4885 |
| US-20200317662-A1 | CYCLOHEXYL ACID ISOXAZOLE AZOLES AS LPA ANTAGONISTS | LPAR1, LPAR2, LPAR3 | KDM4C 3852/4885SLCO1B1 724/4885NPC1 635/4885 |
| US-20200317655-A1 | ISOXAZOLE O-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR4, LPAR6 | KDM4C 2398/4885SLCO1B1 2785/4885NPC1 846/4885 |
| US-11180488-B2 | Isoxazole o-linked carbamoyl cyclohexyl acids as LPA antagonists | LPAR3, LPAR6, LPAR4 | KDM4C 2419/4885SLCO1B1 2732/4885NPC1 887/4885 |
| US-20200317656-A1 | CYCLOHEXYL ACID ISOXAZOLE AZINES AS LPA ANTAGONISTS | LPAR1, LPAR2, LPAR5 | KDM4C 4092/4885SLCO1B1 1008/4885NPC1 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.